Ertapenem Dosing in Moderate Renal Impairment
For a patient with eGFR 44 mL/min, administer ertapenem 500 mg once daily intravenously, as this patient has moderate renal impairment that does not yet require dose adjustment according to FDA labeling, but warrants close monitoring for neurotoxicity. 1
Renal Function Assessment
Your patient's parameters indicate:
- Creatinine 1.57 mg/dL
- BUN 16 mg/dL
- eGFR 44 mL/min
This represents moderate renal impairment (CKD Stage 3b). Using the Cockcroft-Gault equation (which the FDA label references), you should calculate creatinine clearance to confirm the exact dosing category, as eGFR and CrCl can differ significantly 1.
FDA-Approved Dosing Algorithm
The FDA label provides clear cutoffs 1:
- CrCl >30 mL/min/1.73 m²: Standard dose of 1 gram once daily (no adjustment needed)
- CrCl ≤30 mL/min/1.73 m²: Reduced dose of 500 mg once daily
- End-stage renal disease (CrCl ≤10 mL/min/1.73 m²): 500 mg daily with supplemental 150 mg post-hemodialysis if dosed within 6 hours before dialysis
Critical Clinical Consideration
Your patient sits in a high-risk zone. While the eGFR of 44 mL/min technically falls above the 30 mL/min threshold, several factors demand caution:
Neurotoxicity Risk Factors Present
Research demonstrates that moderate renal impairment (CrCl 31-59 mL/min) can lead to excessive ertapenem accumulation and neurotoxicity, even with standard dosing 2, 3. Your patient may benefit from the reduced 500 mg dose because:
- Pharmacokinetic data shows AUC increases 53% in moderate RI and 158% in advanced RI 4
- Half-life extends from 4.5 hours (normal) to 6.1 hours in moderate RI 4
- Case reports document confusional states, seizures, and encephalopathy in patients with CrCl <50 mL/min receiving standard doses 2, 5, 6
Recommended Approach
Start with 500 mg once daily rather than the full 1 gram dose, given:
- The eGFR is borderline and may fluctuate
- Ertapenem has high lipophilicity and CNS penetration 3
- Neurotoxicity can be insidious and prolonged (lasting up to 2 weeks even after discontinuation) 3
Monitoring Requirements
Monitor renal function every 2-3 days during treatment 2. If CrCl drops to ≤30 mL/min during therapy, the 500 mg dose becomes mandatory 1.
Watch for early neurotoxicity signs 2, 5, 6:
- Confusion or altered mental status
- Tremors, myoclonic jerks, asterixis
- Gait instability or dysarthria
- New-onset seizures (even in patients with previously controlled epilepsy)
Duration and Route
- Intravenous infusion over 30 minutes 1
- Maximum duration: 14 days IV (or 7 days IM if applicable) 1
- Complete infusion within 6 hours of reconstitution 1
Critical Pitfall to Avoid
Do not assume the standard 1 gram dose is safe simply because eGFR >30 mL/min. Multiple case reports demonstrate that the FDA-recommended dose reduction threshold may be too conservative, particularly in elderly patients or those with additional risk factors like hypoalbuminemia 2, 3. The 500 mg dose provides adequate antimicrobial coverage while substantially reducing neurotoxicity risk 4.